Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.
Conyers R, Halman A, Moore C, Stenta T, Felmingham B, Collier L, Khatri D, Spelman T, Williams E, Dyas R, Kotecha RS, Jessop S, Mateos MK, Swen J, Elliott DA. Conyers R, et al. Among authors: mateos mk. BMJ Open. 2024 May 16;14(5):e085115. doi: 10.1136/bmjopen-2024-085115. BMJ Open. 2024. PMID: 38760050 Free PMC article.
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L, Martín-Sánchez M, Mateos MV, Ocio EM, Garayoa M, Paíno T. Díaz-Tejedor A, et al. Among authors: mateos mv. Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718. Int J Mol Sci. 2024. PMID: 38731936 Free PMC article.
A research center's experience of T-cell redirecting therapies in triple-class refractory multiple myeloma.
Puertas B, Fernández-Sánchez A, Alejo E, Rey-Bua B, Martín-López AÁ, Pérez López E, Lopez-Parra M, Lopez-Corral L, Gutierrez NC, García-Sanz R, Puig N, Gonzalez-Calle V, Mateos MV. Puertas B, et al. Among authors: mateos mv. Blood Adv. 2024 May 8:bloodadvances.2024012773. doi: 10.1182/bloodadvances.2024012773. Online ahead of print. Blood Adv. 2024. PMID: 38717869
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: mateos mv. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Among authors: mateos mv. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
753 results